Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease - PubMed (original) (raw)
. 2012 Dec;47(12):1488-93.
doi: 10.3109/00365521.2012.725093. Epub 2012 Nov 8.
Affiliations
- PMID: 23137022
- DOI: 10.3109/00365521.2012.725093
Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease
Yusuf Yilmaz et al. Scand J Gastroenterol. 2012 Dec.
Abstract
Background and aims: Syndecan-1 (CD138) is a transmembrane heparan sulfate proteoglycan expressed in the liver which may exert metabolic effects by mediating the hepatic clearance of triglyceride-rich lipoproteins. In the present study, we assayed serum levels and the hepatic expression of syndecan-1 and examined their association with clinical, biochemical, and histologic phenotypes in patients with histology-proven nonalcoholic fatty liver disease (NAFLD).
Methods: A total of 59 patients with biopsy-proven NAFLD and 54 matched controls were enrolled. The analysis of syndecan-1 expression in liver biopsies was performed by immunohistochemistry on formalin-fixed, paraffin-embedded samples. Serum syndecan-1 levels were measured by ELISA.
Results: NAFLD patients had significantly higher serum syndecan-1 levels [median: 61 ng/mL (interquartile range: 36-97 ng/mL)] than controls [median: 37 ng/mL (interquartile range: 25-59 ng/mL, Mann-Whitney U test, p < 0.001]. However, we did not find any significant association between serum syndecan-1 and the mean syndecan-1 immunohistochemical score (n = 59, r = 0.064, p = 0.63). Interestingly, the syndecan-1 immunohistochemical score was an independent predictor of HDL cholesterol in NAFLD patients (β = 0.27; t = 1.99, p < 0.05).
Conclusions: Our data suggest that serum syndecan-1 levels are raised in patients with NAFLD. Moreover, the syndecan-1 immunohistochemical score in the liver is independently associated with HDL cholesterol in this group of patients. These pilot results support further investigation of this molecule in metabolic liver diseases.
Similar articles
- Serum galectin-3 levels in patients with nonalcoholic fatty liver disease.
Yilmaz Y, Eren F, Kurt R, Yonal O, Polat Z, Senates E, Bacha M, Imeryuz N. Yilmaz Y, et al. Clin Biochem. 2011 Aug;44(12):955-8. doi: 10.1016/j.clinbiochem.2011.05.015. Epub 2011 May 24. Clin Biochem. 2011. PMID: 21635880 - Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease.
Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Aktas B, et al. Metabolism. 2011 Apr;60(4):544-9. doi: 10.1016/j.metabol.2010.05.008. Epub 2010 Jun 26. Metabolism. 2011. PMID: 20580037 - Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis.
Yilmaz Y, Eren F, Ayyildiz T, Colak Y, Kurt R, Senates E, Tuncer I, Dolar E, Imeryuz N. Yilmaz Y, et al. Clin Chim Acta. 2011 Nov 20;412(23-24):2296-9. doi: 10.1016/j.cca.2011.08.025. Epub 2011 Aug 24. Clin Chim Acta. 2011. PMID: 21888902 - CD138 (syndecan-1) expression in health and disease.
Palaiologou M, Delladetsima I, Tiniakos D. Palaiologou M, et al. Histol Histopathol. 2014 Feb;29(2):177-89. doi: 10.14670/HH-29.177. Epub 2013 Oct 23. Histol Histopathol. 2014. PMID: 24150912 Review. - Raised Serum Levels of Syndecan-1 (CD138), in a Case of Acute Idiopathic Systemic Capillary Leak Syndrome (SCLS) (Clarkson's Disease).
Bøe OW, Sveen K, Børset M, Druey KM. Bøe OW, et al. Am J Case Rep. 2018 Feb 16;19:176-182. doi: 10.12659/ajcr.906514. Am J Case Rep. 2018. PMID: 29449526 Free PMC article. Review.
Cited by
- The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.
Roy AM, Iyer R, Chakraborty S. Roy AM, et al. Cell Rep Med. 2023 Sep 19;4(9):101170. doi: 10.1016/j.xcrm.2023.101170. Epub 2023 Aug 30. Cell Rep Med. 2023. PMID: 37652015 Free PMC article. Review. - Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease.
Huang H, Awuah WA, Garg T, Ng JC, Mehta A, Ramamoorthy K, Kalmanovich J, Hasan MM. Huang H, et al. Ann Med Surg (Lond). 2023 May 8;85(6):2743-2748. doi: 10.1097/MS9.0000000000000743. eCollection 2023 Jun. Ann Med Surg (Lond). 2023. PMID: 37363524 Free PMC article. - Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma.
Dituri F, Gigante G, Scialpi R, Mancarella S, Fabregat I, Giannelli G. Dituri F, et al. Cancers (Basel). 2022 Apr 9;14(8):1902. doi: 10.3390/cancers14081902. Cancers (Basel). 2022. PMID: 35454809 Free PMC article. Review. - Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis.
Charchanti A, Kanavaros P, Koniaris E, Kataki A, Glantzounis G, Agnantis NJ, Goussia AC. Charchanti A, et al. In Vivo. 2021 Jan-Feb;35(1):333-339. doi: 10.21873/invivo.12264. In Vivo. 2021. PMID: 33402482 Free PMC article. - Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients' Assessment.
Miftode RS, Şerban IL, Timpau AS, Miftode IL, Ion A, Buburuz AM, Costache AD, Costache II. Miftode RS, et al. Cardiol Res Pract. 2019 Nov 11;2019:4750580. doi: 10.1155/2019/4750580. eCollection 2019. Cardiol Res Pract. 2019. PMID: 31815014 Free PMC article. Review.